[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2022129913A1 - Dérivés d'alcyne servant d'inhibiteurs de c-abl - Google Patents

Dérivés d'alcyne servant d'inhibiteurs de c-abl Download PDF

Info

Publication number
WO2022129913A1
WO2022129913A1 PCT/GB2021/053319 GB2021053319W WO2022129913A1 WO 2022129913 A1 WO2022129913 A1 WO 2022129913A1 GB 2021053319 W GB2021053319 W GB 2021053319W WO 2022129913 A1 WO2022129913 A1 WO 2022129913A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyridin
optionally substituted
ethynyl
difluoro
Prior art date
Application number
PCT/GB2021/053319
Other languages
English (en)
Inventor
Rebecca PAUL
Michael LAINCHBURY
Márton VASS
Andrew Cronin
Mark Rackham
Original Assignee
Benevolentai Bio Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevolentai Bio Limited filed Critical Benevolentai Bio Limited
Publication of WO2022129913A1 publication Critical patent/WO2022129913A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds of Formula (I), and in particular Formulae (II) and (III), which are inhibitors of c-ABL.
  • the invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial.
  • medical conditions include neurodegenerative diseases and cancer.
  • ABL1 (Abelson Murine Leukaemia Viral Oncogene Homolog 1) is a protein that exhibits tyrosine kinase enzymatic activity and is associated with various cell functions. In humans, this protein is encoded by the ABL1 gene located on chromosome 9. The version of the ABL1 gene found within the mammalian genome is denoted c-Abl.
  • Philadelphia chromosome is a genetic abnormality in chromosome 22 formed by the t(9,22) reciprocal chromosome translocation, resulting in a fusion gene denoted BCR-ABL1 .
  • This fusion gene contains the ABL1 gene from chromosome 9 and part of the BCR gene.
  • the tyrosine kinase activity of the ABL1 protein is normally tightly regulated, however, the BCR domains in the fusion gene result in constitutive activation of the ABL1 kinase.
  • the binding domains of BCR- ABL and c-ABL are identical.
  • c-Abl Activation of c-Abl has been implicated in various diseases, notably cancer.
  • CML chronic myeloid leukaemia
  • ALL acute lymphocytic leukaemia
  • ALL acute lymphoblastic leukaemia
  • Nilotinib and Ponatinib are both c-Abl inhibitors that have been used in the treatment of chronic myeloid leukaemia (CML) and acute lymphocytic leukaemia (ALL).
  • CML chronic myeloid leukaemia
  • ALL acute lymphoblastic leukaemia
  • AML acute myelogenous leukaemia
  • MPAL mixed-phenotype acute leukaemia
  • CNS central nervous system
  • Neurodegenerative diseases may be characterised by progressive degeneration and ultimate death of neurons.
  • Particular neurodegenerative diseases include amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
  • ALS amyotrophic lateral sclerosis
  • PD Parkinson’s disease
  • ALS is a fatal neurodegenerative disease caused by the progressive degeneration of motor neurons. It has been reported that c-Abl signalling activation contributes to neuronal apoptosis and that c-Abl inhibitors can prevent motor neuron death [Rojas et al. Frontiers in Cellular Neuroscience, 2015, 9, 203; Imamura et al. Science Translational Medicine, 2017],
  • Parkinson’s disease is a progressive neurodegenerative disorder caused by a selective loss of dopaminergic neurons in the substantia nigra pars compacta. It has been reported that c-Abl is activated in the brain of patients with PD and that c-Abl inhibition can protect against dopamine neuronal loss [Pagan et al. Pharmacology Research & Perspectives, 2019; Karuppagounder et al. Scientific Reports, 2014, 4, 4874],
  • Activation of c-Abl has also been implicated in a wide range of other diseases including, but not limited to, prion diseases, viral infections, diabetes, inflammatory diseases such as pulmonary fibrosis, and skeletal or muscular dystrophies.
  • Viral infections can be mediated by ABL1 kinase activity, as in the case of poxviruses and the Ebola virus.
  • Gleevec® and Tasigna® have been shown to stop the release of Ebola viral particles from infected cells, in vitro (see for instance WO 2007/002441 ; Mayra et al. Productive Replication of Ebola Virus Is Regulated by the ABL1 Tyrosine Kinase Science translational medicine 2012, 4, 123ra24). Inhibition of the ABL kinase can therefore be expected to reduce the pathogen's ability to replicate. In prion disease models, Gleevec® showed beneficial effects.
  • ABL1 inhibitors represent a valid therapeutic approach for the treatment of prion diseases, such as Creutzfeldt-Jacob disease (CJD).
  • X-linked recessive Emery-Dreifuss muscular dystrophy is caused by mutations of emerin, a nuclear-membrane protein with roles in nuclear architecture, gene regulation and signalling.
  • emerin a nuclear-membrane protein with roles in nuclear architecture, gene regulation and signalling.
  • a study has shown that emerin is tyrosine- phosphorylated directly by ABL1 in cell models, and that the phosphorylation status of emerin changes emerin binding to other proteins such as BAF. This, in turn, may explain the mislocalization of mutant emerin from nuclear to cytosolic compartments and consequently changes in downstream effector and signal integrator for signalling pathway(s) at the nuclear envelope (Tifft et al.
  • ABL1 kinase plays a role in inflammation and oxidative stress, two mechanisms that are implicated in a variety of human diseases ranging from acute CNS diseases, such as stroke and traumatic brain or spinal cord injuries, chronic CNS diseases, such as Alzheimer's, Parkinson's, Huntington's and motoneuron diseases, to non-CNS inflammatory and autoimmune diseases, such as diabetes, pulmonary fibrosis.
  • acute CNS diseases such as stroke and traumatic brain or spinal cord injuries
  • chronic CNS diseases such as Alzheimer's, Parkinson's, Huntington's and motoneuron diseases
  • non-CNS inflammatory and autoimmune diseases such as diabetes, pulmonary fibrosis.
  • Gleevec® prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis (Akhmetshina et al.
  • imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum. 2009, 60, 219-24) and it shows antifibrotic effects in bleomycin-induced pulmonary fibrosis in mice (Aono et al. Imatinib as a novel antifibrotic agent in bleomycin- induced pulmonary fibrosis in mice Am. J. Respir. Grit. Care Med. 2005, 171 , 1279-85). Another study showed that both imatinib and nilotinib attenuated bleomycin-induced acute lung injury and pulmonary fibrosis in mice (Rhee et al.
  • nilotinib Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 2011 , 82, 273-87). Although in these studies the authors were focusing on the implication the mechanism related to PDGFRs, of interest, in the study by Rhee et al. (Respiration. 2011 , 82, 273-87), nilotinib which is a more potent c-ABL inhibitor than imatinib showed superior therapeutic antifibrotic effects, thus supporting the therapeutic applicability of c-ABL inhibitors for treatment of human diseases with pulmonary inflammation.
  • compounds of Formula (I) may inhibit c-ABL and therefore treat or prevent the above medical conditions. Further, they have certain beneficial properties leading to increased potential for use as a drug compared to known compounds. This may be in terms of their efficacy, efflux profile (P-pg and/or BCRP), free brain level at C m ax, solubility, selectivity profiles, such as kinase selectivity, low hERG inhibitory activity, safety profile, and/or other notable pharmacokinetic properties.
  • the first aspect of the invention relates to a compound of Formula
  • Het is an optionally substituted 5- or 6-membered monocyclic heteroaryl or an optionally substituted 8- to 10-membered bicyclic heteroaryl;
  • Each Y is C or N, wherein one Y is C and one Y is N;
  • Z is C or O; n is 0, 1 , 2, 3, 4, 5, or 6, preferably 0, 1 , 2, or 3;
  • R 1 is selected from the group consisting of H, halo, and C1-C3 alkyl, wherein the C1-C3 alkyl is optionally substituted with one or more halo atoms; and each R 2 is independently selected from the group consisting of halo, and C1-C3 alkyl, wherein the C1-C3 alkyl is optionally substituted with one or more halo atoms; with the proviso that Het is not unsubstituted pyridyl.
  • the surprising beneficial properties of the compounds of the invention may be attributed, in part, to the partially saturated fused bicyclic ring system attached to the amide group in the compounds of Formula (I), particularly when combined with the optionally substituted 5- or 6- membered monocyclic heteroaryl or optionally substituted 8- to 10-membered bicyclic heteroaryl of group Het. It has been unexpectedly found that compounds that comprise the partially saturated fused bicyclic ring have high BAF3/ABL inhibitory activity (indicated by low IC50 values) and low P-gp efflux and BCRP efflux, making them particularly useful in the treatment of certain diseases and conditions. It is noted that P-gp/BCRP efflux is unpredictable and must be established empirically. Overcoming the challenges associated with delivering therapeutic agents with low susceptibility to efflux presents a major challenge to treatment of many disorders, particularly disorders affecting the brain.
  • P-glycoprotein 1 also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243) is an important protein of the cell membrane that pumps many foreign substances out of cells. It is an ATP-dependent efflux pump with broad substrate specificity, and is likely evolved as a defence mechanism against harmful substances.
  • P-gp is extensively distributed and expressed in the capillary endothelial cells composing the blood-brain barrier (as well as the blood-testis barrier) where it pumps xenobiotics (such as toxins or drugs) back into the capillaries.
  • BCRP Breast cancer resistance protein
  • ABCG2 ATP-binding cassette super-family G member 2
  • unsubstituted pyridyl means a monovalent radical of pyridine with only hydrogen atoms attached to the ring except for the point at which it is attached to the remainder of the compound. Therefore, in compounds of the invention, Het is not one of the following unsubstituted groups:
  • Het may be any suitable optionally substituted 5- or 6-membered monocyclic heteroaryl or optionally substituted 8- to 10- membered bicyclic heteroaryl.
  • 5- or 6-membered monocylic heteroaryl is an aromatic monocyclic hydrocarbon ring in which at least one, such as 1 , 2, 3, or 4, ring atom is a heteroatom.
  • 8- to 10-membered bicyclic heteroaryl is a heteroaromatic fused bicyclic ring system in which at least one, such as 1 , 2, 3, or 4, ring atom is a heteroatom.
  • Het is an optionally substituted 5- or 6- membered monocyclic heteroaryl or an optionally substituted 9- or 10-membered bicyclic heteroaryl.
  • Het is selected from the group consisting of optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolizinyl, indazolyl, benzimidazolyl, pyrrolopyridinyl, azaindazolyl, pyrazolopyrimidinyl, purinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, benzoisoxazolyl, benzoisothiazolyl, benzoxazolyl, benzothiazolyl, furopyridinyl,
  • pyrrolyl More preferably it is selected from optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolopyridinyl, furopyridinyl, and naphthyridinyl. Most preferably it is selected from optionally substituted imidazolyl, pyridyl, pyrimidinyl, napthyridinyl, and furopyridinyl.
  • Preferable examples of 5- or 6-membered heteroaryls for group Het may be in the following regioisomeric forms or a tautomer thereof, with each group being optionally substituted, including substitution of the H attached to a N atom. More preferably they may be the following regioisomeric forms or a tautomer thereof, with each group being optionally substituted, including substitution of the H attached to a N atom.
  • Preferable examples of 8- or 10-membered heteroaryls for group Het may be in the following regioisomeric forms with each group being optionally substituted, including substitution of the H attached to a N atom. More preferably they may be the following regioisomeric forms with each group being optionally substituted.
  • Het is selected from one of the following groups: each of which being optionally substituted, including substitution of the H attached to a N atom.
  • Het may be substituted with one or more substituents, as mentioned above.
  • the substitution is one or more of the groups selected from the group consisting of
  • Ce-Cio aryl, C1-C9 heteroaryl, and C1-C9 heterocycle each of which is optionally substituted with one or more substituents independently selected from halo and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with one or more halo atoms.
  • Each R 3 , R 4 , and R 5 is independently selected from the group consisting of H and C1-C3 alkyl, wherein the C1-C3 alkyl is optionally substituted with one or more halo atoms.
  • More preferred optional substituents for Het are selected from the group consisting of:
  • 4- to 7-membered heterocycle is a non-aromatic monocyclic ring system having 4 to 7 ring atoms, in which at least one ring atom is a heteroatom.
  • 4- to 7-membered heterocycles include azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, and piperazinyl, more preferably azetidinyl and pyrrolidinyl, each of which are optionally substituted as described above.
  • the 4- to 7-memebered heterocycle is one of the following groups, each of which are optionally substited as described above:
  • the 5-membered monocyclic heteroaryl as a substituent on Het include pyrrolyl, pyrazolyl, imidazolyl, triazolyl, and tetrazolyl, more preferably pyrazolyl and triazole, each of which are optionally substituted as described above.
  • the 5-membered monocyclic heteroaryl is one of the following groups, each of which are optionally substituted as described above:
  • Het is a 6-membered heteroaryl group
  • the hydrogen-bonding substituent is located at the 4-position relative to the point of attachment to the remainder of the compound.
  • Het is a 5-memebered heteroaryl group
  • the hydrogenbonding substituent is located at the 3-position relative to the point of attachment to the remainder of the compound.
  • Het is selected from one of the following groups: each of which being optionally substituted, wherein each R 6 is independently selected from the group consisting of -NHR 4 and -C(O)NHR 4 .
  • Z is C or O. It will be understood that when Z is C, it will be attached to two H, each of which may be independently substituted with R 2 in accordance with the definion of n.
  • the compound of Formula (I) is a compound of Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof, wherein each X is independently halo, preferably F;
  • R 1 is H or C1-C3 alkyl, preferably H, ethyl, or cyclopropyl, most preferably H; and Het is as defined above for Formula (I).
  • Het is selected from one of the following groups: each of which is optionally substituted with one or more substituents independently selected from the group consisting of
  • the compound of Formula (I) is a compound of Formula (III) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof, wherein Het is as defined above for Formula (I).
  • Het is selected from one of the following groups: each of which is optionally substituted with one or more substituents independently selected from the group consisting of
  • the compounds of the invention may include isotopically-labelled and/or isotopically-enriched forms of the compounds.
  • the compounds of the invention herein may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N,
  • the compounds of the invention may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof.
  • pharmacologically acceptable addition salts mentioned below are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form.
  • Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
  • Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
  • organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluen
  • Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
  • the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
  • a given chemical formula or name shall also encompass all pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and/or prodrug forms thereof. It is to be understood that the compounds of the invention include any and all hydrates and/or solvates of the compound formulas. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulas are to be understood to include and represent those various hydrates and/or solvates.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1 H- and 3H-imidazole, 1 H, 2H- and 4H- 1 ,2,4-triazole, 1 H- and 2H- isoindole, and 1 H- and 2H-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • the compounds described herein can be asymmetric (e.g. having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • the invention relates to the D form, the L form, and D,L mixtures and also, where more than one asymmetric carbon atom is present, to the diastereomeric forms.
  • Those compounds of the invention which contain asymmetric carbon atoms, and which as a rule accrue as racemates, can be separated into the optically active isomers in a known manner, for example using an optically active acid.
  • prodrugs refers to compounds that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention.
  • a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention.
  • Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, e.g. by hydrolysis in the blood.
  • the prodrug compound usually offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see Silverman, R. B., The Organic Chemistry of Drug Design and Drug Action, 2nd Ed., Elsevier Academic Press (2004), page 498 to 549).
  • Prodrugs of a compound of the invention may be prepared by modifying functional groups, such as a hydroxy, amino or mercapto groups, present in a compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
  • Examples of prodrugs include, but are not limited to, acetate, formate and succinate derivatives of hydroxy functional groups or phenyl carbamate derivatives of amino functional groups.
  • Another object of the present invention relates to the compounds of the invention for use in therapy.
  • the compounds of the invention are useful as inhibitors of c-ABL. As such, they are useful in the treatment or prevention of medical conditions (conditions or diseases) in which inhibition of c-ABL is beneficial.
  • a method of for the treatment or prevention of a disease or condition responsive to c-ABL inhibition comprising administering a therapeutically effective amount of a compound of the invention to a subject.
  • the compounds of the invention may be suitable to prevent a range of diseases and conditions, it is preferable that they are used to treat said diseases and conditions. Therefore, it is preferred that the method is for the treatment of a disease or condition, and therefore the method comprises administering a therapeutically effective amount of a compound of the invention to a subject in need thereof.
  • treatment may include prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.
  • prevention refers to prophylaxis of the named disorder or condition.
  • the range of diseases and conditions treatable or preventable by c-ABL inhibition is well known.
  • the compounds of the invention therefore may be used to treat or prevent this range of diseases or conditions.
  • This includes neurodegenerative disorders, cancers, prion diseases, viral infections, diabetes, inflammatory diseases such as pulmonary fibrosis, or a skeletal or muscular dystrophy.
  • the disease is a neurodegenerative disorder or a cancer.
  • Treatable or preventable neurodegenerative disorders include, but are not limited to, Alzheimer disease, Down’s syndrome, frontotemporal dementia, progressive supranuclear palsy, Pick’s disease, Niemann-Pick disease, Parkinson’s disease, Huntington’s disease (HD), dentatorubropallidoluysian atrophy, Kennedy’s disease, and spinocerebellar ataxia, fragile X (Rett’s) syndrome, fragile XE mental retardation, Friedreich’s ataxia, myotonic dystrophy, spinocerebellar ataxia type 8, and spinocerebellar ataxia type 12, Alexander disease, Alper’s disease, amyotrophic lateral sclerosis (ALS), ataxia telangiectasia, Batten disease, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt- Jakob disease, ischemia stroke, Krabbe disease, Lewy body dementia, multiple sclerosis, multiple system atrophy, Pelizaeus-M
  • Treatable or preventable cancers include, but are not limited to, leukaemia.
  • CML chronic myeloid leukaemia
  • ALL acute lymphoblastic leukaemia
  • AML acute myelogenous leukaemia
  • MPAL mixed-phenotype acute leukaemia
  • CNS central nervous system
  • the cancer is CML or ALL.
  • the invention thus includes the use of the compounds of the invention in the manufacture of a medicament for the treatment or prevention of a disease or condition, such as the above-mentioned neurodegenerative disorders and cancers.
  • the invention also relates to the compounds of the invention for use in the treatment of a disease or condition, such as the above-mentioned neurodegenerative disorders and cancers.
  • Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
  • the methods herein include those further comprising monitoring subject response to the treatment administrations.
  • monitoring may include periodic sampling of subject tissue, fluids, specimens, cells, proteins, chemical markers, genetic materials, etc. as markers or indicators of the treatment regimen.
  • the subject is pre-screened or identified as in need of such treatment by assessment for a relevant marker or indicator of suitability for such treatment.
  • the invention provides a method of monitoring treatment progress. The method includes the step of determining a level of diagnostic marker (Marker) (e.g.
  • the level of Marker determined in the method can be compared to known levels of Marker in either healthy normal controls or in other afflicted patients to establish the subject's disease status.
  • a second level of Marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy.
  • a pre-treatment level of Marker in the subject is determined prior to beginning treatment according to this invention; this pretreatment level of Marker can then be compared to the level of Marker in the subject after the treatment commences, to determine the efficacy of the treatment.
  • a level of Marker or Marker activity in a subject may be determined at least once. Comparison of Marker levels, e.g., to another measurement of Marker level obtained previously or subsequently from the same patient, another patient, or a normal subject, may be useful in determining whether therapy according to the invention is having the desired effect, and thereby permitting adjustment of dosage levels as appropriate. Determination of Marker levels may be performed using any suitable sampling/expression assay method known in the art or described herein. Preferably, a tissue or fluid sample is first removed from a subject. Examples of suitable samples include blood, urine, tissue, mouth or cheek cells, and hair samples containing roots. Other suitable samples would be known to the person skilled in the art.
  • Determination of protein levels and/or mRNA levels (e.g., Marker levels) in the sample can be performed using any suitable technique known in the art, including, but not limited to, enzyme immunoassay, is ELISA, radiolabeling/assay techniques, blotting/chemiluminescence methods, real-time PCR, and the like.
  • enzyme immunoassay is ELISA
  • radiolabeling/assay techniques e.g., radiolabeling/assay techniques
  • blotting/chemiluminescence methods e.g., blotting/chemiluminescence methods, real-time PCR, and the like.
  • the compounds disclosed herein are formulated into pharmaceutical compositions (or formulations) for various modes of administration. It will be appreciated that compounds of the invention may be administered together with a physiologically acceptable carrier, excipient, and/or diluent (i.e. one, two, or all three of these).
  • compositions disclosed herein may be administered by any suitable route, preferably by oral, rectal, nasal, topical (including buccal and sublingual), sublingual, transdermal, intrathecal, transmucosal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • Other formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy.
  • Pharmaceutical formulations are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutically acceptable carriers, diluents or excipients.
  • excipients examples include water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
  • Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.
  • the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and more preferably between 1-50% by weight in preparations for oral administration.
  • the formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc.
  • the formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections.
  • Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner. To maintain therapeutically effective plasma concentrations for extended periods of time, compounds disclosed herein may be incorporated into slow release formulations.
  • the dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy.
  • the daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen.
  • substituted means that the group to which it refers has one or more hydrogen atoms substituted for a different group.
  • substituted pyrazolyl refers to a monovalent radical of pyrazole with one or more hydrogens attached to the ring being repaced with another group.
  • heteroatom means O, N, or S. Typically, it is preferred that the heteroatom or heteroatoms in the 5- or 6-membered heteroaryl group is nitrogen.
  • Ci-Ce alkyl denotes a straight, branched or cyclic or partially cyclic alkyl group having from 1 to 6 carbon atoms, i.e. 1 , 2, 3, 4, 5 or 6 carbon atoms.
  • Ci-Ce alkyl group to comprise a cyclic portion it should be formed of 3 to 6 carbon atoms.
  • Ci-Ce alkyl all subgroups thereof are contemplated, such as C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, Ci alkyl, C2-C6 alkyl, C2-C5 alkyl, C2-C4 alkyl, C2-C3 alkyl, C2 alkyl, C3-C6 alkyl, C3-C5 alkyl, C3-C4 alkyl, C3 alkyl, C4-C6 alkyl, C4-C5 alkyl, C4 alkyl, Cs-Ce alkyl, C5 alkyl, and Ce alkyl.
  • Ci-Ce alkyl examples include methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, cyclopropylmethyl, and straight, branched or cyclic or partially cyclic pentyl and hexyl etc.
  • a term denotes a range, for instance “1 to 6 carbon atoms” in the definition of Ci-C 6 alkyl, each integer is considered to be disclosed, i.e. 1 , 2, 3, 4, 5 and 6.
  • C2-C6 alkenyl denotes a straight, branched or cyclic or partially cyclic alkyl group having at least one carbon-carbon double bond, and having from 2 to 6 carbon atoms.
  • the alkenyl group may comprise a ring formed of 3 to 6 carbon atoms.
  • C2-C6 alkenyl all subgroups thereof are contemplated, such as C2-C5 alkenyl, C2-C4 alkenyl, C2-C3 alkenyl, C2 alkenyl, Cs- Ce alkenyl, C3-C5 alkenyl, C3-C4 alkenyl, C3 alkenyl, C4-C6 alkenyl, C4-C5 alkenyl, C4 alkenyl, Cs-Ce alkenyl, C5 alkenyl, and Ce alkenyl.
  • C2-C6 alkenyl examples include 2-propenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 2-hexenyl, 5- hexenyl, 2,3-dimethyl-2-butenyl.
  • C2-C6 alkynyl denotes a straight, branched or cyclic or partially cyclic alkyl group having at least one carbon-carbon triple bond, and having from 2 to 6 carbon atoms.
  • the alkynyl group may comprise a ring formed of 3 to 6 carbon atoms.
  • C2-C6 alkynyl all subgroups thereof are contemplated, such as C2-C5 alkynyl, C2-C4 alkynyl, C2-C3 alkynyl, C2 alkynyl, Cs- Ce alkynyl, C3-C5 alkynyl, C3-C4 alkynyl, C3 alkynyl, C4-C6 alkynyl, C4-C5 alkynyl, C4 alkynyl, Cs-Ce alkynyl, C5 alkynyl, and Ce alkynyl.
  • C2-C6 alkynyl examples include 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-methyl-4-pentynyl, 2- hexynyl, 5-hexynyl etc.
  • Ci-Ce alkoxy denotes -O-(Ci-Cealkyl) in which a Ci-Ce alkyl group is as defined above and is attached to the remainder of the compound through an oxygen atom.
  • Ci-Ce alkoxy examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy and straight- and branched- chain pentoxy and hexoxy.
  • halo means a halogen atom, and is preferably, F, Cl, Br and I, more preferably F and Cl, and most preferably F.
  • Ce-C aryl denotes an aromatic monocyclic or fused bicyclic hydrocarbon ring comprising 6 to 10 ring atoms.
  • Examples of “Ce-Cw aryl” groups include phenyl, indenyl, naphthyl, and naphthalene.
  • C1-C9 heteroaryl denotes an aromatic monocyclic or fused bicyclic heteroaromatic ring system having 5 to 10 ring atoms in which 1 to 9 of the ring atoms are carbon and one or more of the ring atoms are selected from nitrogen, sulphur, and oxygen.
  • C1-C9 heteroaryl examples include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, tetrazolyl, quinazolinyl, indolyl, indolinyl, isoindolyl, isoindolinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinolinyl, quinoxalinyl, thiadiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 1 ,3-benzodioxolyl, 1 ,4-benzodioxinyl, 2,3- dihydro-1 ,4-benzodioxinyl, benzothiazolyl, benzimidazolyl, benzothiadiazolyl, benzotri
  • C1-C9 heterocycle denotes a non-aromatic monocyclic or fused bicyclic ring system having 5 to 10 ring atoms containing 1 to 9 carbon atoms and one or more of the ring atoms are selected from nitrogen, sulphur, and oxygen.
  • the ring system may be fully saturated or partially unsaturated.
  • C1-C9 heterocycle examples include piperidinyl, tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, azepinyl, azetidinyl, pyrrolidinyl, morpholinyl, imidazolinyl, imidazolidinyl, thiomorpholinyl, pyranyl, dioxanyl, piperazinyl, homopiperazinyl, and 5,6-dihydro-4H-1 ,3-oxazin-2-yl.
  • “An effective amount” refers to an amount of a compound of the invention that confers a therapeutic effect on the treated subject.
  • the therapeutic effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. subject gives an indication of or feels an effect).
  • the terms “administration” or “administering” mean a route of administration for a compound disclosed herein.
  • Exemplary routes of administration include, but are not limited to, oral, intravenous, intraperitoneal, intraarterial, and intramuscular.
  • the preferred route of administration can vary depending on various factors, e.g. the components of the pharmaceutical composition comprising a compound disclosed herein, site of the potential or actual disease and severity of disease.
  • subject and “patient” are used herein interchangeably. They refer to a human or another mammal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate) that can be afflicted with or is susceptible to a disease or disorder but may or may not have the disease or disorder. It is preferred that the subject is human.
  • mammal e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate
  • the subject is human.
  • Compounds of the invention may be disclosed by the name or chemical structure. If a discrepancy exists between the name of a compound and its associated chemical structure, then the chemical structure prevails.
  • the compounds of formula (I) disclosed herein may be prepared by, or in analogy with, conventional methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art.
  • the necessary starting materials for preparing the compounds of formula (I) are either commercially available, or may be prepared by methods known in the art.
  • the compounds of formula (I) may possess one or more chiral carbon atoms, and they may therefore be obtained in the form of optical isomers, e.g., as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
  • the separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may, for example, be achieved by fractional crystallization of salts with optically active (chiral) acids or by chromatographic separation on chiral columns.
  • a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of addition salt forming acids are mentioned above.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • protecting groups are t-butoxycarbonyl (Boc), benzyl and trityl(triphenylmethyl).
  • the methods described below may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R.
  • Agilent 1100 (quaternary pump) XBridge-C18, 5 pm, 4.6 x 50 mm, 25 °C, 2 mL/min, 5 pL injection, 5 % MeCN in H 2 O (+10 mM ammonium formate), gradient 5-95 % over 3.5 min, hold for 1 min, 200-400 nm.
  • reaction mixture was filtered through a syringe filter.
  • Another portion of cyclopropylboronic acid pinacol ester (281 mg, 1.67mmol) and Pd(PPhs)4 (97mg, 0.08mmol) was added and the mixture was heated to 120°C for 3h in sealed vial under MW irradiation.
  • the reaction mixture was filtered through a syringe filter.
  • Another portion of cyclopropylboronic acid pinacol ester (281 mg, 1.67mmol) and Pd(PPhs)4 (97mg, 0.08mmol) was added and the mixture was heated to 120°C for 3h in sealed vial under MW irradiation.
  • the two reaction mixtures were combined before work-up and purification.
  • tert-butyl 3-(5-amino-3-pyridyl)pyrrolidine-1 -carboxylate 82.0mg, 0.31 mmol
  • MeCN MeCN
  • tert-butyl nitrite 51.9pL, 0.44mmol
  • the mixture was stirred at 0°C for 1 h before CuBr2 (73.0mg, 0.33mmol) was added.
  • the mixture was allowed to warm to rt overnight.
  • the reaction mixture was diluted with DCM (20mL). The solution was washed with H2O (10mL), brine (10mL), dried over Na2SO4 and concentrated to a crude brown residue.
  • N-(4,4-difluoro-6,7-dihydro-5H-pyrazolo[1 ,5-a]pyridin-2- yl)-3-ethynyl-4-methyl-benzamide (60.0mg, 0.19mmol), 3,5-dibromopyridine (67.6mg, 0.29mmol), MeCN (2.0mL) and DIPEA (99.4pL, 0.57mmol).
  • the reaction mixture was degassed using nitrogen, Cui (1.8mg, 0.01 mmol) and PdCl2( hs)2 (6.7mg, 0.01 mmol) were added and reaction was heated under MW irradiation for 60min at 100°C.
  • the mixture was degassed for 30min before addition of trans N,N'-dimethylcyclohexane-1 ,2-diamine (0.75mL, 4.75mmol), followed by a degassed solution of 2-bromo-5,5-dimethyl-6,8-dihydroimidazo[2,1- c][1 ,4]oxazine (1.08g, 4.67mmol) in 1 ,4-dioxane (20mL) and the resultant mixture heated to 100°C overnight under N2. The reaction was allowed to cool to rt, filtered through cotton wool and concentrated in vacuo. The green oil was solubilized in DCM (100mL), washed with sat. aq.
  • the reaction mixture was concentrated in vacuo, the sample was redissolved in MeOH (50 mL), K2CO3 (3.00g, 21.7mmol) was added and the mixture was stirred for 1 h at rt. An additional portion of K2CO3 (3.00g, 21.7mmol) was added after 15min.
  • the reaction mixture was concentrated in vacuo and the sample was redissolved in EtOAc (75mL) and H2O (75mL). The aqueous phase was extracted with EtOAc (2x35mL) and the combined organic phases were washed with brine (50mL) and concentrated in vacuo.
  • the sample was purified on silica (reverse phase, 10% to 100% MeOH in 10% MeOH/H2O) and dried in a vacuum oven at 60°C for 18h to give the title compound (1.40g, 37%) as a dark black solid.
  • UPLC Method G 2.76 min, 100 %.
  • Methyl 3-bromo-4-fluoro-benzoate (1.00g, 4.30mmol), 3-ethynylpyridine (665mg, 6.45mmol), triethylamine (1 ,82mL, 13.1 mmol) and EtOAc (20mL) were added to a two-neck round bottom flask, degassed with N2 for 15 min, then Cui (26.8mg, 0.14mmol) and Pd(PPhs)2Cl2 (85.0mg, 0.12mmol) were added and the resulting mixture was stirred at rt under N2 overnight. The reaction mixture was allowed to cool to rt, filtered through a celite pad and concentrated.
  • a RBF was charged with methyl 4-fluoro-3-[2-(3-pyridyl)ethynyl]benzoate (208mg, 0.81 mmol), CS2CO3 (797mg, 2.44mmol), pyrazole (56mg, 0.81 mmol) and DMF (15mL) and heated to 80°C for 0.5h under a N2 atmosphere.
  • the reaction mixture was allowed to cool to rt, the solvent partially removed, the residue diluted with H2O (15mL) and EtOAc (20mL) and the layers separated.
  • the aqueous layer was extracted with EtOAc (3x30mL), combined organics were dried over Na2SO4, filtered, and concentrated to give a beige solid.
  • reaction mixture was allowed to cool to rt, filtered through a celite pad and concentrated.
  • the residue was purified on silica (Biotage Isolera, reverse phase, MeCN:H2O, 1 :9 to 4:1 , both eluents containing 0.1 Vol% NH3) to give the title compound (124mg, 23%) as a colourless solid.
  • reaction mixture was allowed to cool to rt, filtered through a celite pad and concentrated.
  • the residue was purified on silica (Biotage Isolera, reverse phase, MeCN:H2O, 1 :9 to 7:3, both eluents containing 0.1 Vol% HCO2H) to give a semi-pure white powder.
  • the powder was further purified on silica (Biotage Isolera, reverse phase, MeCN:H2O, 1 :9 to 7:3, both eluents containing 0.1 Vol% NH3) to give the title compound (4.80mg, 6%).
  • UPLC Method
  • the resulting solution was then heated at 80°C for 1 h.
  • the reaction mixture was cooled down and left to stand at rt for 18h.
  • the reaction mixture was concentrated in vacuo and the crude was purified on silica (Biotage Isolera, reverse phase, MeCN:H2O, 9:11 to 100% MeCN, both eluents containing 0.1 Vol% NH3).
  • the residue was then recrystallised from a hot mixture of MeOH:H2O (10mL, 1 :1) and filtered to afford the desired product.
  • the filtrate, rich in product was concentrated to remove MeOH and the resulting aqueous was freeze dried.
  • the freeze dried residue gave a second batch of the desired product.
  • N-(4,4-difluoro-6,7-dihydro-5H-pyrazolo[1 ,5-a]pyridin-2-yl)-4-methyl-3-[2-(5- pyrrolidin-3-yl-3-pyridyl)ethynyl]benzamide dihydrochloride (20.0mg, 0.04mmol) was dissolved in DCM (5.0mL) and washed with K2CO3 (sat. aq. 5.0mL). The organic was collected and the aqueous extracted with DCM (2 x 5.0mL). The combined organic extracts were dried over Na2SO4 and concentrated to a yellow oil.
  • Ponatinib was purchased commercially from AK Scientific, Inc. COMPARATIVE EXAMPLE 2
  • Nilotinib was purchased commercially from Medchem Tronica.
  • 6-Fluoro-4-iodo-isoquinolin-3-amine (185.0mg, 0.59mmol, 91.7% pure), 3- ethynyl-4-methyl-N-[1-(2-morpholinoethyl)pyrazol-3-yl]benzamide (160.0mg, 0.45mmol, 96% pure), EtsN (75.9pL, 0.54mmol), Pd(PPhs)2Cl2 (8.0mg, 11.3pmol) and Cui (3.0mg, 15.9pmol) were added to MeCN (5.0mL) and the reaction heated under reflux at 82°C for3h. The mixture was filtered through Celite and concentrated in vacuo.
  • the residue was purified by reverse phase HPLC (ACE-5AQ, 100 x 21.2mm, 5pm, 25mL per min, gradient 0% to 100% (over 7min) then 100% (3 min) MeOH in 10% MeOH/IYO).
  • the residue was then repurified by reverse phase HPLC (Phenomenex Synergi Hydro-RP 80A AXIA, 100 x 21.2mm, 4pm, 25mL per min, gradient 20% to 100% (over 7 min) then 100% (3 min) MeOH in 10% MeOH/H2O) [1% formic acid]).
  • the material was de-salted by treating with sat. aq. NaHCOs and extracted into DCM and concentrated in vacuo.
  • the CellTiter-Glo luminescent cell viability assay is a homogeneous method of determining the number of viable cells in culture based on quantification of the ATP present. Briefly, IL-3 dependent Ba/F3 cells are modified to express BCR- ABL. Activity of the transformed kinase overrides IL-3 dependency for cellular proliferation and survival. Test compounds that specifically inhibit kinase activity lead to programmed cell death which can be measured through the addition of CellTiter-Glo reagent.
  • Ba/F3 cells expressing BCR-ABL (Advanced Cellular Dynamics) or parental Ba/F3 (control) cells were prepared at 5x10 4 /mL in RPMI 1640 containing 10% FBS, 1 x Glutamax and 750ng/mL puromycin.
  • Test compounds were dispensed into 384 well plates using the Tecan D300e at a top final assay concentration of 10pM with dosing normalised to 0.1 % DMSO in 50pL volume. 50pL cells were added to each well of the prepared 384 well plates and the plates spun at OOrpm for 1 min prior to incubation at 37°C, 5% CO2 for 48h. After 48h 15pL CellTiterGlo reagent was added to each well in the plate. Following a 60 min incubation at rt luminescence was read on the Pherastar FS reader.
  • pICso data are calculated as the -logio(ICso in Molar). Those data show that the compounds of the invention can inhibit c-Abl.
  • Wild-type MDCK, MDR1-MDCK and BCRP-MDCK cells were seeded into 24 well Transwell plates and cultured for 3 days to form monolayers.
  • Test compound were prepared at 1 M in Hanks’ Balanced Salt Solution containing 25 mM HEPES and loaded into the donor compartments of Transwell plates bearing the cell monolayers (pH 7.4 for both donor and receiver compartments).
  • Lucifer Yellow was added to the apical buffer in all wells to assess integrity of the cell monolayer.
  • Duplicate wells were prepared and incubated at 37°C in a CO2 incubator. Samples were removed at time zero and 60 min and test compound analysed by LC- MS/MS. Concentrations of Lucifer Yellow in the samples was measured using a fluorescence plate reader.
  • the apparent permeability (Papp) values of test compound was determined for both the apical to basal (A>B) and basal to apical (B>A) permeation and the efflux ratio (B>A: A>B) determined in each cell line.
  • the effective efflux ratio was determined from the ratio of either M DR 1 -MDCK cells or BCRP-MDCK cells relative to the ratio observed in wild-type cells. A higher value represent a better substrate for the efflux mechanism, which is less preferable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), et en particulier des formules (II) et (III), qui sont des inhibiteurs de c-ABL. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés, et leur utilisation dans le traitement ou la prévention d'états médicaux dans lesquels l'inhibition de c-Abl est bénéfique. De telles affections médicales comprennent des maladies neurodégénératives et le cancer.
PCT/GB2021/053319 2020-12-16 2021-12-16 Dérivés d'alcyne servant d'inhibiteurs de c-abl WO2022129913A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2019874.3 2020-12-16
GBGB2019874.3A GB202019874D0 (en) 2020-12-16 2020-12-16 New compounds and methods

Publications (1)

Publication Number Publication Date
WO2022129913A1 true WO2022129913A1 (fr) 2022-06-23

Family

ID=74188946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/053319 WO2022129913A1 (fr) 2020-12-16 2021-12-16 Dérivés d'alcyne servant d'inhibiteurs de c-abl

Country Status (2)

Country Link
GB (1) GB202019874D0 (fr)
WO (1) WO2022129913A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241170A2 (fr) 2001-03-16 2002-09-18 Pfizer Limited Dérivés de pyrazolopyrimidine
WO2007002441A1 (fr) 2005-06-24 2007-01-04 Emory University Procedes d'utilisation d'inhibiteurs de tyrosine kinase competitive non atp afin de traiter des infections pathogenes
US20140045826A1 (en) * 2011-04-07 2014-02-13 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
WO2018068739A1 (fr) * 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 Composé hétérocyclique d'alcynyle pour inhiber l'activité de la protéine kinase
WO2020260871A1 (fr) * 2019-06-24 2020-12-30 Benevolentai Bio Limited Nouveaux composés et procédés

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241170A2 (fr) 2001-03-16 2002-09-18 Pfizer Limited Dérivés de pyrazolopyrimidine
WO2007002441A1 (fr) 2005-06-24 2007-01-04 Emory University Procedes d'utilisation d'inhibiteurs de tyrosine kinase competitive non atp afin de traiter des infections pathogenes
US20140045826A1 (en) * 2011-04-07 2014-02-13 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
WO2018068739A1 (fr) * 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 Composé hétérocyclique d'alcynyle pour inhiber l'activité de la protéine kinase
WO2020260871A1 (fr) * 2019-06-24 2020-12-30 Benevolentai Bio Limited Nouveaux composés et procédés

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS
AKHMETSHINA ET AL.: "Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis", ARTHRITIS RHEUM., vol. 60, 2009, pages 219 - 24, XP009144496
AONO ET AL.: "Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice", AM. J. RESPIR. CRIT. CARE MED., vol. 171, 2005, pages 1279 - 85
ERTMER ET AL.: "The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells", J. BIOL. CHEM., vol. 279, 2004, pages 41918 - 27
HUANG ET AL.: "Imatinib attenuates skeletal muscle dystrophy in mdx mice", FASEB J., vol. 23, 2009, pages 2539 - 48, XP055481456, DOI: 10.1096/fj.09-129833
HUANG WEI-SHENG ET AL: "Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{ 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 12, 24 June 2010 (2010-06-24), pages 4701 - 4719, XP002615777, ISSN: 0022-2623, [retrieved on 20100601], DOI: 10.1021/JM100395Q *
IMAMURA ET AL., SCIENCE TRANSLATIONAL MEDICINE, 2017
KARUPPAGOUNDER ET AL., SCIENTIFIC REPORTS, vol. 4, 2014, pages 4874
L. FIESERM. FIESER: "Fieser and Fieser's Reagents for Organic Synthesis", 1994, JOHN WILEY AND SONS
MAYRA ET AL., PRODUCTIVE REPLICATION OF EBOLA VIRUS IS REGULATED BY THE ABL1 TYROSINE KINASE SCIENCE TRANSLATIONAL MEDICINE, vol. 4, 2012, pages 123ra24
PAGAN ET AL., PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019
R. LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
RHEE ET AL., RESPIRATION, vol. 82, 2011, pages 273 - 87
RHEE ET AL.: "Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice", RESPIRATION, vol. 82, 2011, pages 273 - 87
ROJAS ET AL., FRONTIERS IN CELLULAR NEUROSCIENCE, vol. 9, 2015, pages 203
SILVERMAN, R. B.: "The Organic Chemistry of Drug Design and Drug Action", 2004, ELSEVIER ACADEMIC PRESS, pages: 498 - 549
SINGLETON ET AL.: "Dynamin 2 and c-Abl are novel regulators of hyperoxia-mediated NADPH oxidase activation and reactive oxygen species production in caveolin-enriched microdomains of the endothelium", J. BIOL. CHEM., vol. 284, 2009, pages 34964 - 75, XP002748171, DOI: 10.1074/jbc.M109.013771
T.W. GREENEP.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS
TIFFT ET AL.: "Tyrosine phosphorylation of nuclear- membrane protein emerin by SRC, ABL1 and other kinases", J. CELL SCI., vol. 122, 2009, pages 3780 - 90
YUN ET AL.: "The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery", J NEUROVIROL., vol. 13, 2007, pages 328 - 37

Also Published As

Publication number Publication date
GB202019874D0 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
JP6708661B2 (ja) Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物
CN107531668B (zh) 治疗性哒嗪化合物及其用途
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
JP5832524B2 (ja) ピリドン及びアザピリドン化合物、並びにそれらの使用方法
JP2018109013A (ja) キナーゼ調節のための化合物および方法、ならびにその適応
CN108884077A (zh) 糖苷酶抑制剂
JP2019515931A (ja) イソキノリン−３イル−カルボキサミドならびにその調製および使用の方法
CN108884078A (zh) 糖苷酶抑制剂
CN103596952A (zh) 作为Syk抑制剂的新型取代的吡啶并吡嗪类化合物
US20200299265A1 (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
TW201803869A (zh) 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
JP2020537671A (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
CN111526890A (zh) 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
US20230014226A1 (en) New compounds and methods
WO2022129913A1 (fr) Dérivés d'alcyne servant d'inhibiteurs de c-abl
EP4028387A1 (fr) Nouveaux composés et procédés
WO2022129915A1 (fr) Dérivés de pyrazole en tant qu'inhibiteurs de c-abl
WO2022129914A1 (fr) Dérivés d'alcyne en tant qu'inhibiteurs de c-abl
TWI673268B (zh) 作為ｆｇｆｒ４抑制劑之稠環雙環吡啶基衍生物
AU2022407039A1 (en) Pyrimidines and methods of their use
WO2024167950A1 (fr) Composés et compositions utiles comme agents de dégradation de la kinase mk2
EA040315B1 (ru) Способы лечения болезни хантингтона

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21831336

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21831336

Country of ref document: EP

Kind code of ref document: A1